Skip to main content
. Author manuscript; available in PMC: 2016 Apr 18.
Published in final edited form as: Expert Opin Drug Deliv. 2015 Mar 26;12(9):1459–1473. doi: 10.1517/17425247.2015.1018175

Figure 4.

Figure 4

(A) Schematic of NP transport across the intestinal epithelium using the FcRn transcytosis pathway. (B) Immunohistochemistry on mouse duodenum tissue sections showing expression of the FcRn in the intestinal epithelium. Mouse FcRn appears brown in the images. The negative control for the staining was polyclonal IgG. (C) Biodistribution of 14C-labeled NPs after oral administration to mice demonstrating that NP-Fc were able to enter systemic circulation and reach the liver, lungs, and spleen significantly more than non-targeted NPs. (D) Blood glucose response of fasted mice to orally administered NPs. NP-Fc was able to generate a significantly greater hypoglycemic response than non-targeted NPs. Adapted with permission from ref. [106].